Try a new search

Format these results:

Searched for:

person:fonacl01

in-biosketch:true

Total Results:

89


Taking Advantage of our EMR to Take Better Care of our Allergic Rhinitis Patients [Meeting Abstract]

Feldman, Eleanor; Fonacier, Luz; Banta, Erin; Mawhirt, Stephanie; Schneider, Amanda
ISI:000629158000570
ISSN: 0091-6749
CID: 4820622

Pruritus, Sleep, and Productivity: A Post Hoc Analysis of Abrocitinib Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) From JADE MONO-2 [Meeting Abstract]

Yosipovitch, Gil; Fonacier, Luz; Stander, Sonja; Su, John; Gooderham, Melinda; Szepietowski, Jacek; Deleuran, Mette; Girolomoni, Giampiero; Biswas, Pinaki; Feeney, Claire; Valdez, Hernan; Rojo, Ricardo; Thorpe, Andrew; Chan, Gary; Cappelleri, Joseph; DiBonaventura, Marco; Myers, Daniela
ISI:000629158000106
ISSN: 0091-6749
CID: 4821192

Real Time Assessment of Steroid Use in Patients with Atopic Dermatitis [Meeting Abstract]

Sani, Sonam; Mawhirt, Stephanie; Banta, Erin; Schneider, Amanda; Fonacier, Luz
ISI:000629158000101
ISSN: 0091-6749
CID: 4821182

Occupational Contact Dermatitis: An Update

Milam, Emily C; Nassau, Stacy; Banta, Erin; Fonacier, Luz; Cohen, David E
Occupation contact dermatitis (CD) is a common inflammatory skin condition impacting every professional industry in the United States. It is associated with significant personal and professional distress, loss of revenue, and decreased productivity. Occupational CD is further subdivided into irritant CD and allergic CD. Frequently, workers may suffer from a combination of both types. Numerous workplace exposures are implicated, but there are several themes across professions, such as CD related to frequent handwashing and wet work. A detailed occupational history, physical examination, and patch testing can help to make the diagnosis. Treatment includes identification of the substance and avoidance, which often is quite challenging.
PMID: 33161959
ISSN: 2213-2201
CID: 4684222

Concomitant Treatment with Omalizumab and Cyclosporine for Chronic Spontaneous Urticaria: a case series

Rosenblum, Jake D; Nassau, Stacy; Fonacier, Luz; Mawhirt, Stephanie L
BACKGROUND:Severe asthma (SA) often requires subspecialist management and treatment with biologic therapies and/or maintenance systemic corticosteroids (mSCS). OBJECTIVE:To describe contemporary, real-world biologic and mSCS use among U.S., subspecialist-treated patients with SA. METHODS:CHRONICLE is an ongoing, noninterventional study of U.S. adults with SA treated by allergists/immunologists or pulmonologists. Eligible patients are receiving biologics and/or mSCS or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers (HD ICS+). Biologic and mSCS use patterns and patient characteristics were summarized for patients enrolled between February 2018 and February 2019. RESULTS:Among protocol-eligible patients, 58% and 12% were receiving biologics and mSCS respectively, with 7% receiving both. Among 796 enrolled, most were female (67%), non-Hispanic white (71%), of suburban residence (50%), and had elevated body mass index (median 31). Respiratory and nonrespiratory comorbidities were highly prevalent. With biologics (n=557), 51% were anti-IgE and 48% were anti-IL5/IL-5Rα; from May 2018, 76% of initiations were anti-IL-5/IL-5Rα. In patients receiving mSCS, median prednisone-equivalent daily dose was 10 mg. Multivariate logistic regression demonstrated patients of hospital clinics, sites with fewer nonphysician staff, and with a recorded concurrent chronic obstructive pulmonary disease diagnosis were less likely to receive biologics and more likely to receive mSCS. CONCLUSION/CONCLUSIONS:In this real-world sample of U.S., subspecialist-treated patients with SA not controlled by HD ICS+, mSCS use was infrequent and biologic use was common, with similar prevalence of anti-IgE and anti-IL-5/IL-5Rα biologics. Treatment differences associated with patient and site characteristics should be investigated to ensure equitable access to biologics and minimize mSCS use.
PMID: 32360694
ISSN: 1534-4436
CID: 4427882

A Hands-on Approach to Contact Dermatitis and Patch Testing

Schmidlin, Kristin; Sani, Sonam; Bernstein, David I; Fonacier, Luz
Contact dermatitis (CD) is a common skin condition caused by contact with an exogenous agent that elicits an inflammatory response. While history and physical exam can be helpful in distinguishing between irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD), the gold standard for diagnosing ACD is patch testing. While the actual patch test (PT) procedure and application is relatively straightforward, the decisions involving which allergens to use, interpretation of results, determination of relevant allergens and subsequent patient management requires more skill and expertise. Often, the distribution of the presenting dermatitis can provide insight into the potential causative allergens and should be taken into account when selecting PT allergens. Commercially available PT panels and personal care products can be used for patch testing. Determining the clinical relevance of PT results is a critical component of the PT procedure. Patients must be educated on avoidance of relevant allergens and given guidance on alternative products available for use. Special populations, including children with ACD, occupational contact dermatitis (OCD), and patients with biomedical devices have unique allergen considerations and PT panels should be directed as such to address all potential allergens.
PMID: 32112924
ISSN: 2213-2201
CID: 4324962

Utility of an EMR-Tool to Monitor Total Steroid Burden in Patients with Atopic Dermatitis and Asthma [Meeting Abstract]

Sani, S; Banta, E; Mawhirt, S; Noor, I; Schneider, A; Nassau, S; Feldman, E; Fonacier, L
Rationale: Cutaneous, inhaled, intranasal and systemic corticosteroids(CS) are commonly prescribed for the treatment of atopic dermatitis(AD), asthma, and allergic rhinitis. The cumulative burden of these steroids in individual patients are not routinely assessed by providers and can lead to adverse effects. We sought to use an EMR-tool to increase documentation of the total steroid burden(SB) in our patients with atopic dermatitis and asthma.
Method(s): A SB EMR-tool was used for 99 AD encounters and 64 asthma encounters over an 18-month period. Data collected included corticosteroid type, potency, frequency, side effects, interventions and counseling.
Result(s): There were 99 AD encounters assessed in 58 patients(53% female, mean age of 31). Of these 99 encounters using topical corticosteroids(TCS), 24 were using inhaled CS; 12 using intranasal CS and 8 using systemic CS. The most common side effects encountered while on TCS included: pigment changes(n=20), skin atrophy(n=11), easy bruising(n=7), telangiectasias(n=6), striae(n=6), rosacea(n=3), and hair growth(n=2). Twenty-eight encounters(28%) had an intervention: 10 decreased dose, 3 decreased potency and 15 discontinued TCS. 85 encounters(86%) documented patient counseling. There were 64 asthma encounters assessed in 49 patients(63% female, mean age of 56). Of these 64 encounters using inhaled CS, 27 were using intranasal CS and 18 using systemic CS. The most common side effects encountered while using inhaled CS included: candidiasis(n=6) and hoarseness(n=1). Four encounters(6.25%) had an intervention: 3 decreased dose, 1 discontinuation. 62 encounters(97%) documented patient counseling.
Conclusion(s): Using our EMR-tool facilitates the identification and tracking of total SB in patients, associated side effects and leads to meaningful intervention.
Copyright
EMBASE:2004874715
ISSN: 1097-6825
CID: 4315122

Validation of five patient-reported outcomes for atopic dermatitis severity in adults

Silverberg, J I; Margolis, D J; Boguniewicz, M; Fonacier, L; Grayson, M H; Ong, P Y; Fuxench, Z C; Simpson, E L
BACKGROUND:Structured patient-reported outcomes of AD severity are not standardized in clinical practice. We sought to determine the construct validity, internal consistency, cross-cultural validity, floor or ceiling effects of multiple AD severity assessments. METHODS:A cross-sectional, population-based study of 2893 adults, including 602 adults that met a modified UK Diagnostic Criteria for AD. AD severity was assessed using self-reported global AD severity, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Scoring AD (PO-SCORAD) and its objective and subjective components, and numerical rating scale (NRS)-itch. QOL was assessed using short-form (SF-)12 mental and physical health scores, SF-6D health utility scores, Dermatology Life Quality Index (DLQI). Hospital Anxiety and Depression Scale (HADS) was assessed. RESULTS:PO-SCORAD, PO-SCORAD objective and subjective sub-scores, NRS-itch and POEM all had moderate to strong correlations with each other, and DLQI, fair to moderate correlations with HADS-A and HADS-D, and inverse correlations with SF-12 MCS and SF-6D (Pearson correlations, P<0.0001). All scores showed good criterion validity as judged by analysis of variance and receiver operator characteristics. PO-SCORAD, PO-SCORAD objective sub-scores and POEM had similarly good internal consistency (Cronbach's alpha=0.84, 0.82 and 0.86); PO-SCORAD subjective sub-score was less internally consistent (alpha=0.57). All scores showed potentially poor cross-cultural validity as demonstrated by uniform and non-uniform differential item functioning by age, sex and/or race/ethnicity for multiple items. There were floor effects for POEM, but not for the other assessments CONCLUSIONS: PO-SCORAD, PO-SCORAD objective and subjective sub-scores, NRS-itch and POEM appear to be valid for assessing AD severity in clinical practice.
PMID: 30972740
ISSN: 1365-2133
CID: 3854102

Allergic Contact Dermatitis

Nassau, Stacy; Fonacier, Luz
Allergic contact dermatitis is common, resulting in considerable morbidity. Diagnosis is based on a thorough history, physical examination, and patch testing. Several commercially available panels of patch testing are currently used. Allergens are found in a wide variety of daily products, occupational exposures, and foods. The mainstay of treatment is avoidance of the allergen, and databases like Contact Allergen Management Program and Contact Allergen Replacement Database help patients to select products that do not contain allergens to which they are sensitized. Topical corticosteroids can be used to treat exacerbations, but should be avoided in long-term treatment.
PMID: 31757238
ISSN: 1557-9859
CID: 4215482

Pain is a common and burdensome symptom of atopic dermatitis in United States adults

Silverberg, Jonathan I; Gelfand, Joel M; Margolis, David J; Boguniewicz, Mark; Fonacier, Luz; Grayson, Mitchell H; Chiesa Fuxench, Zelma C; Simpson, Eric L; Ong, Peck Y
OBJECTIVE:Characterize the frequency, intensity, characteristics and associations of pain from AD. METHODS:A cross-sectional, US population internet survey-based study of 602 adults with AD from the AD in America study was performed (modified UK Working Party Criteria). RESULTS:Overall, 365 (61%) reported pain from AD, with 199 (33%) experiencing pain at least once per week and 30 (5%) with pain daily. Among those with AD pain, 22% reported worst pain intensity ≥7. Frequency and intensity of AD pain were associated with PO-SCORAD, PO-SCORAD-itch and -sleep, and POEM (P≤0.004 for all). Among those experiencing AD pain, 179 (48%) reported pain occurring only after frequent scratching, 156 (42%) reported intermittent pain and 27 (11%) reported constant pain throughout the day. AD pain was most commonly associated with open areas caused by scratching (27%) and fissures in the skin (27%), followed by inflamed red skin (25%), with only a minority reporting pain mostly caused by burning from creams or ointments (10%). Mild AD was associated with more pain from scratching, whereas severe AD was associated with more constant pain and pain from inflamed skin. CONCLUSION/CONCLUSIONS:Pain is a distinct symptom in AD, with heterogeneous frequency, characteristics, intensity and QOL impact. Pain was related to scratching, fissures, and/or inflamed red skin, and least from burning from topical medications. Skin pain should be assessed in AD patients and monitoring treatment response.
PMID: 31228619
ISSN: 2213-2201
CID: 3967632